Argenx Se (ARGX) Operating Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Operating Income came in at $493.0 million in Q2 2026, up 145.2% YoY from $201.1 million in Q2 2025, and up 25.13% on a QoQ basis from $394.0 million in Q1 2026.
Argenx Se (ARGX) Operating Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Operating Income data on file, last reported at $493.0 million in Q2 2026.
- Quarterly Operating Income rose 145.2% year-over-year to $493.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 250.06% YoY) and the FY2025 annual result came in at $1.1 billion, up 4966.57% from the prior year.
- Operating Income grew to $493.0 million in Q2 2026, from $394.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $493.0 million in Q2 2026 to a low of -$222.7 million in Q1 2022.
- A 5-year average of $54.5 million and a median of -$15.6 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 3036.48% — and 2025, when it jumped 2340.22%.
- Tracing ARGX's Operating Income over 5 years: stood at -$114.4 million in 2022, then decreased by 21.14% to -$138.6 million in 2023, then jumped by 174.33% to $103.0 million in 2024, then surged by 256.76% to $367.6 million in 2025, then soared by 34.11% to $493.0 million in 2026.
- The last three Operating Income figures came in at $493.0 million (Q2 2026), $394.0 million (Q1 2026), and $367.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 493.00 Mn |
| Mar 31, 2026 | 394.00 Mn |
| Dec 31, 2025 | 367.61 Mn |
| Sep 30, 2025 | 346.19 Mn |
| Jun 30, 2025 | 201.06 Mn |
| Mar 31, 2025 | 139.00 Mn |
| Dec 31, 2024 | 103.04 Mn |
| Sep 30, 2024 | 14.19 Mn |
| Jun 30, 2024 | -45.46 Mn |
| Mar 31, 2024 | -93.42 Mn |
| Dec 31, 2023 | -138.62 Mn |
| Sep 30, 2023 | -80.59 Mn |
| Jun 30, 2023 | -102.09 Mn |
| Mar 31, 2023 | 103.74 Mn |
| Dec 31, 2022 | -114.43 Mn |
| Sep 30, 2022 | -208.64 Mn |
| Jun 30, 2022 | -174.54 Mn |
| Mar 31, 2022 | -222.73 Mn |
| Dec 31, 2021 | -230.91 Mn |
| Sep 30, 2021 | 7.11 Mn |